Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

Year marked by strengthened leadership team and the initiation of Phase 3

program for cetrorelix in BPH

All amounts are in U.S. dollars

QUEBEC CITY, March 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and full year ended December 31, 2007.

David J. Mazzo, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "2007 was a challenging year; a year marked by important changes to both our corporate structure and business plan. The result has given our stakeholders a sharper image of our objectives and ongoing priorities. 2007 also involved a great deal of groundbreaking, marking for example, the first time our team launched an international Phase 3 program as is the case for cetrorelix in BPH. Another first was the opening of our offices in New Jersey as part of our strategy to gain more exposure with the pharmaceutical and financial communities in the United States. Furthermore, following the appointment of three new key executives during the year, we now have a team of the highest level in clinical research, regulatory affairs, business development, pharmaceutical discovery, development and commercialization - vital assets for the successful pre-launch activities for cetrorelix, as well as for the thrust of our entire pipeline.

Moving forward, we will continue to strive to expose the depth, breadth and potential of our robust pipeline and will diligently execute our business plan with the primary objective of creating value for our shareholders."

CONSOLIDATED RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2007

Consolidated revenues were $10.2 million for the fourth quarter ended December 31, 2007 compared to $11.9 million for the same quarter in 2006. The decrease in revenues is attributable to lower sales of Impavido(R), as well as active pharmaceutical ingredients to the Company's partners, combined with lower license fees from the Company's partners.

Selling, General and Administrative (SG&A) expenses were $5.1 million for the fourth quarter ended December 31, 2007 compared to $4.2 million for the same quarter in 2006. The increase in SG&A is mainly related to the support of the continuation of a Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH) and the opening of a new operational headquarters in New Jersey.

Consolidated Research & Development (R&D) expenses were $13.6 million for the fourth quarter ended December 31, 2007 compared to $7.9 million for the same quarter in 2006. The increase in R&D expenses relates to the continuation of the Company's Phase 3 program with cetrorelix in BPH.

Consolidated net loss was $13.6 million or $0.26 per basic and diluted share for the fourth quarter ended December 31, 2007 compared to consolidated net earnings of $39.1 million or $0.74 per basic and diluted share for the same quarter in 2006. The increased net loss in the fourth quarter 2007 is related to higher loss from operations of nearly $5.2 million mainly related to increased R&D expenses, as well as to lower income tax recovery of nearly $28.4 million attributable to the recognition of future income tax assets mainly related to the sale of Atrium shares in 2006 and the special distribution of the Company's remaining interest in January 2007, combined with the decrease in net earnings from Atrium's discontinued operations of approximately $16.3 million.

The consolidated cash and short-term investments were $41.4 million as of December 31, 2007.

CONSOLIDATED RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2007

Consolidated revenues for the year ended December 31, 2007 were $42.1 million compared to $38.8 million for the same period in 2006. The increase in revenues for 2007 is mainly related to increased sales of Cetrotide(R) and Impavido(R), partly compensated by lower license fees revenues from the Company's partners.

Consolidated R&D costs were $39.2 million for the year ended December 31, 2007 compared to $27.4 million for the same period in 2006. The increase in R&D expenses of $11.8 million in 2007 is mainly related to the advancement of the Company's lead product cetrorelix in Phase 3 for BPH; as well as to further advancement of targeted, earlier-stage development programs including AEZS-108, a cytotoxic conjugate and AEZS-112, a tubulin inhibitor.

Consolidated loss from operations increased to $34.8 million for the year ended December 31, 2007 compared to $23.8 million for the same period in 2006. The increase in loss from operations in 2007 is attributable to a combination of lower license revenues, increase in non-recurring G&A corporate expenses and additional R&D expenses mainly related to the advancement of the Company's Phase 3 program with cetrorelix in BPH. This increase in loss from operations in 2007 was partly offset by increased sales and royalties, as well as lower D&A expenses.

Consolidated net loss was $32.3 million or $0.61 per basic and diluted share for the year ended December 31, 2007 compared to consolidated net earnings of $33.4 million or $0.64 per basic share and $0.62 per diluted share for the same period in 2006. The increased net loss in 2007 is related to a higher loss from operations of nearly $10 million, lower income tax recovery of nearly $27 million related to the recognition of future income tax assets, mainly attributable to the sale of Atrium shares in 2006, and the special distribution of AEterna Zentaris' remaining interest in January 2007, as well as lower net earnings from discontinued operations of Atrium of nearly $26 million.

CONFERENCE CALL

Management will be hosting a conference call for the investment community beginning at 10:00 a.m. Eastern Time today, Wednesday, March 5, to discuss fourth quarter and full-year 2007 results.

To participate in the live conference call by telephone, please dial 416-644-3425, 514-807-8791 or 800-595-8550. Individuals interested in listening to the conference call on the Internet may do so by visiting http://www.aezsinc.com. A replay will be available on the Company's Web site for 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.

Attachment: Financial summary

(In thousands of

US dollars,

except share

and per share data)

Three months ended Year ended

CONSOLIDATED RESULTS December 31, December 31,

Unaudited 2007 2006 2007 2006

-------------------------------------------------------------------------

-------------------------------------------------------------------------

$ $ $ $

Revenues

Sales and royalties 6,435 6,800 28,825 25,123

License fees 3,705 5,137 12,843 13,652

Other 100 - 400 24

-------------------------------------------------------------------------

10,240 11,937 42,068 38,799

-------------------------------------------------------------------------

Operating expenses

Cost of sales, excluding

depreciation and

amortization 3,255 3,556 12,930 11,270

Selling, general and

administrative 5,146 4,159 20,403 16,478

R&D costs 13,574 7,926 39,248 27,422

R&D tax credits and grants (1,941) (1,442) (2,060) (1,564)

Depreciation and

amortization 1,135 4,195 5,566 8,964

Impairment of long-lived

asset held for sale 735 - 735 -

-------------------------------------------------------------------------

21,904 18,394 76,822 62,570

-------------------------------------------------------------------------

Loss from operations (11,664) (6,457) (34,754) (23,771)

-------------------------------------------------------------------------

Other revenues (expenses)

Interest income 535 703 1,904 1,441

Interest expense (23) 14 (85) (1,433)

Foreign exchange gain

(loss) (269) 384 (1,035) 319

Loss on disposal of

equipment (28) - (28) -

Gain on disposal of

long-term investment - 409 - 409

Other - (163) - -

-------------------------------------------------------------------------

215 1,347 756 736

-------------------------------------------------------------------------

Share in the results

of an affiliated

company - 1,575 - 1,575

-------------------------------------------------------------------------

Loss before Income taxes (11,449) (3,535) (33,998) (21,460)

Income tax recovery

(expense) (2,405) 26,061 1,961 29,037

-------------------------------------------------------------------------

Net earnings (loss) from

continuing operations (13,854) 22,526 (32,037) 7,577

Net earnings (loss) from

discontinued operations 218 16,575 (259) 25,813

-------------------------------------------------------------------------

Net earnings (loss) for

the year (13,636) 39,101 (32,296) 33,390

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net earnings (loss) per

share from continuing

operations

Basic and diluted (0.26) 0.42 (0.61) 0.14

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Net earnings (loss)

per share

Basic (0.26) 0.74 (0.61) 0.64

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Diluted (0.26) 0.74 (0.61) 0.62

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number

of shares

Basic 53,182,803 52,694,868 53,182,803 52,099,290

Diluted 53,182,803 53,035,786 53,182,803 52,549,260

Issued and outstanding

shares 53,187,470 53,169,470

(In thousands of US dollars, except share

and per share data)

CONSOLIDATED BALANCE SHEET December December

31, 31,

Unaudited 2007 2006

-------------------------------------------------------------------------

-------------------------------------------------------------------------

$ $

Cash and short-term investments 41,387 60,489

Other current assets 18,193 41,234

----------------------

59,580 101,723

Long-term assets 63,783 121,768

----------------------

Total assets 123,363 223,491

----------------------

----------------------

Current liabilities 22,255 16,310

Long-term debt - 687

Other long-term liabilities 12,517 27,615

----------------------

34,772 44,612

Shareholders' equity 88,591 178,879

----------------------

Total liabilities and shareholders' equity 123,363 223,491

----------------------

----------------------


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, ... and current participant in the Phase 1 Ventures program, is leveraging regional and ... Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging ...
(Date:6/22/2016)... ... 22, 2016 , ... The Immigrant Journey Awards , ... to North Texas and the nation, recently held its annual luncheon program. ... civic and economic vitality of North Texas. Proceeds from the event are used ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):